Brief: Knight Therapeutics Announces Health Canada Approval For Nerlynx® (Neratinib) To Treat Her2-Positive Metastatic Breast Cancer
06/07/2021 13:33
July 6 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES HEALTH CANADA APPROVAL FOR
NERLYNX® (NERATINIB) TO TREAT HER2-POSITIVE METASTATIC BREAST
CANCER
Source text for Eikon: ID:nGNX3tSSkS
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil